6-(4-fluorophenyl)pyridin-3-amine | 31676-70-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-(4-fluorophenyl)pyridin-3-amine
• 英文别名: 3-Pyridinamine, 6-(4-fluorophenyl)-
• CAS: 31676-70-7
• 化学式: C₁₁H₉FN₂
• 分子量: 188.204
• InChiKey: BDXIJRSPGKXTBB-UHFFFAOYSA-N

物化性质

• 沸点：
  338.5±27.0 °C(Predicted)
• 密度：
  1.218±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-(4-fluorophenyl)pyridin-3-amine 、 水杨醛 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 0.17h， 生成 2-(((6-(4-fluorophenyl)pyridin-3-yl)amino)methyl)phenol
  参考文献：
  名称：

  Structure–activity relationship study of E6 as a novel necroptosis inducer

  摘要：

  Necroptosis inducers represent a promising potential treatment for drug-resistant cancer. We herein describe the structure modification of E6, which was identified recently as a potent and selective necroptosis inducer. The studies described herein demonstrate for the first time that functionalized biphenyl derivatives possess necroptosis inducer activity. Furthermore, these studies have led to the identification of two promising compounds (5h and 5j) that can be used for further optimization studies as well as mechanism of action investigations. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.04.038
• 作为产物：
  描述：

  5-氨基-2-溴吡啶 、 4-氟苯硼酸 在 dihydrogen dichloro-bis(di-tert-butylphosphinito-κP)palladium(2-) 、 四丁基溴化铵 、 potassium hydroxide 作用下， 以 水 为溶剂， 反应 2.0h， 以57%的产率得到6-(4-fluorophenyl)pyridin-3-amine
  参考文献：
  名称：

  POPd / TBAB共同催化杂芳基氯化物/溴化物与4-氟苯基硼酸在水中的Suzuki交叉偶联反应

  摘要：

  根据Suzuki交叉偶联方案，在水性介质中研究了无杂有机物和高效杂相合成桥联杂芳基卤化物和4-氟苯基硼酸的方法。使用钯次膦酸络合物（POPd）/四丁基溴化铵（TBAB）作为助催化剂，在纯净水中通过以下方法成功获得了高产率的杂芳基-芳基氟化物高产率：根据TBAB中间相的功能，提出并讨论了一种可能的非均相偶联反应机理。报道的方法的显着特性是高度的共催化活性，耐杂原子性，简单的分离程序以及对环境处置的影响很小。

  DOI：

  10.1007/s13738-015-0775-9

文献信息

• [EN] PHTHALIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY<br/>[FR] DÉRIVÉS DE PHTALIMIDE À TITRE DE MODULATEURS DE LA VOIE WNT
  申请人：AGENCY SCIENCE TECH & RES

  公开号：WO2015187094A1

  公开（公告）日：2015-12-10

  The present invention relates to compounds of formula (I), [Formula should be inserted here] pharmaceutically acceptable salts, solvates and polymorphs thereof, including all tautomers and stereoisomers thereof, wherein R1 is alkyl; alkoxy-alkyl-; carbocyclyl; heterocyclyl; aryl; heteroaryl; aryl-alkyl-; heteroaryl- alkyl-; carbocyclyl-alkyl-; or heterocyclyl-alkyl-; R2 is H or alkyl; R3 is H or alkyl; Y is aryl; heteroaryl; carbocyclyl; or heterocyclyl; and Z is aryl; heteroaryl; carbocyclyl; or heterocyclyl.

  本发明涉及化合物的公式（I），其药学上可接受的盐、溶剂和多型体，包括其所有互变异构体和立体异构体，其中R1是烷基；烷氧基烷基；碳环烷基；杂环烷基；芳基；杂芳基；芳基烷基；杂芳基烷基；碳环烷基烷基；或杂环烷基烷基；R2是H或烷基；R3是H或烷基；Y是芳基；杂芳基；碳环烷基；或杂环烷基；Z是芳基；杂芳基；碳环烷基；或杂环烷基。
• [EN] INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS<br/>[FR] INDAZOLE-3-CARBOXAMIDES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA VOIE DE SIGNALISATION PAR WNT/Beta-CATÉNINE
  申请人：SAMUMED LLC

  公开号：WO2013040215A1

  公开（公告）日：2013-03-21

  lndazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole-3- carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

  本文披露了用于治疗各种疾病和病理的吲唑-3-羧酰胺化合物。更具体地，本文涉及使用吲唑-3-羧酰胺化合物或其类似物治疗由Wnt途径信号激活所特征的疾病（例如癌症、异常细胞增殖、血管生成和骨关节炎），调节由Wnt途径信号介导的细胞事件，以及由于Wnt途径和/或Wnt信号组分之一或多个的突变或失调而引起的遗传疾病和神经系统疾病/紊乱/疾病。还提供了治疗与Wnt相关疾病状态的方法。
• [EN] METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS<br/>[FR] PROCÉDÉS D'UTILISATION D'INDAZOLE-3-CARBOXAMIDES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA VOIE DE SIGNALISATION WNT/β-CATÉNINE
  申请人：SAMUMED LLC

  公开号：WO2018075858A1

  公开（公告）日：2018-04-26

  This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing. The methods include administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of one or more indazole-3-carboxamide compounds or salts or analogs thereof as described anywhere herein.

  本公开涉及使用一种或多种吲唑-3-羧酰胺化合物或其盐或类似物，用于治疗独立选择自包括肌腱病、皮炎、牛皮癣、硬皮病、鱼鳞病、雷诺综合征和达里尔病的一种或多种疾病或症状；和/或促进伤口愈合。方法包括向受试者（例如，需要者）施用如本文中任何地方所述的一种或多种吲唑-3-羧酰胺化合物或其盐或类似物的治疗有效量。
• Metal-free C–H arylation of aminoheterocycles with arylhydrazines
  作者：Toshihide Taniguchi、Mitsutaka Imoto、Motonori Takeda、Fukashi Matsumoto、Takeo Nakai、Masatoshi Mihara、Takumi Mizuno、Akihiro Nomoto、Akiya Ogawa

  DOI：10.1016/j.tet.2016.05.056

  日期：2016.7

  A direct C–H arylation of aminoheterocycles with arylhydrazine hydrochlorides was developed. The reaction proceeds via a homolytic aromatic substitution mechanism involving aryl radicals as the intermediates. The new reaction takes place readily at room temperature in air and in the presence of an inexpensive base. Moreover, the reactivity of this radical arylation correlated with the HOMO energy of

  开发了一种直接用氨基芳烃盐酸盐将氨基杂环进行C–H芳基化的方法。该反应通过以芳基为中间体的均质芳族取代机理进行。新反应易于在室温下在空气中和廉价碱存在下进行。而且，该自由基芳基化的反应性与氨基杂环的HOMO能相关。该方法不仅提供了快速进入各种芳基化杂环的途径，而且还是传统的过渡金属催化卤化物与有机金属之间交叉偶联的原子有效替代方法。
• Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
  申请人：sanofi-aventis

  公开号：EP1939181A1

  公开（公告）日：2008-07-02

  The present invention relates to heteroaryl-substituted carboxamides of the formula I, in which Het, A, X, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

  本发明涉及公式I的杂环取代羧酰胺，其中Het、A、X、R1、R2和R3具有索引中指示的含义，这些化合物调节内皮一氧化氮（NO）合酶的转录，并且是有价值的药理活性化合物。具体地，公式I的化合物上调内皮一氧化氮合酶酶的表达，并可应用于需要增加该酶的表达或增加NO水平或正常化降低的NO水平的情况。该发明还涉及公式I化合物的制备方法，包括它们的药物组合物，以及公式I化合物用于制造刺激内皮一氧化氮合酶表达或治疗各种疾病的药物的用途，包括心血管疾病，如动脉粥样硬化、血栓形成、冠状动脉疾病、高血压和心脏功能不全等。